Fulcrum Therapeutics, Inc.
FULCDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How FULC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Losmapimod oral tablet | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Fulcrum Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fulcrum Therapeutics, Inc.'s (FULC) pipeline across Phase 2. Its lead program is Losmapimod oral tablet (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fulcrum Therapeutics, Inc.'s next FDA catalyst?→
Fulcrum Therapeutics, Inc.'s (FULC) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FULC biotech catalysts?→
Add FULC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fulcrum Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.